Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Genetic profiling of NUDT15 in the Slovenian population
Authors:ID Šmid, Alenka (Author)
ID Urbančič, Dunja (Author)
ID Vrevc Žlajpah, Jaka (Author)
ID Stollarova, Natalia (Author)
ID Prelog, Tomaž (Author)
ID Kavčič, Marko (Author)
ID Jazbec, Janez (Author)
ID Mlinarič-Raščan, Irena (Author)
ID Karas Kuželički, Nataša (Author)
Files:.pdf PDF - Presentation file, download (2,05 MB)
MD5: 11549AB1D1AD562223943245F9BDFD25
 
URL URL - Source URL, visit https://www.tandfonline.com/doi/full/10.1080/14622416.2024.2409060
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:Determining variant TPMT alleles to predict patient response to thiopurine therapy represents one of the first successful implementations of pharmacogenomics in clinical practice. However, despite the TPMT-adjusted thiopurine dosing, some TPMT wild-type patients still exhibit toxicity at standard doses. Over the past decade, the pharmacogene NUDT15 has emerged as a significant co-modulator of thiopurine therapy. Initially, NUDT15 was considered important predominantly in Asian populations, but recent studies have highlighted its relevance in European populations as well. To evaluate the pharmacogenetic significance of NUDT15 in the Slovenian population, we sequenced extended regions of exon 1 and exon 3 in 109 healthy individuals and 37 patients with acute lymphoblastic leukemia. We identified eight variants, including one with established clinical significance (allele *3) and one extremely rare variant (Chr13 at 48045861; GRCh38, NC_000013.11). The frequencies of most previously described variants in both the general population and in the ALL cohort were consistent with those reported in other European populations, except for rs45465203, which was less frequent in the Slovenian population. None of the variants, except for NUDT15*3, were associated with cumulative thiopurine doses in ALL patients. However, these variants warrant further investigation in larger ALL cohorts.
Keywords:6-mercaptopurine, acutelymphoblastic leukemia, dose reduction, minorallele frequency, NUDT15, population genetics, thiopurines
Publication status:Published
Publication version:Version of Record
Year of publishing:2024
Number of pages:str. 515-525
Numbering:Vol. 25, no. 12-13
PID:20.500.12556/DiRROS-30162 New window
UDC:616.155.392+575.17
ISSN on article:1744-8042
DOI:10.1080/14622416.2024.2409060 New window
COBISS.SI-ID:213081347 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 28. 10. 2024;
Publication date in DiRROS:16.06.2026
Views:39
Downloads:19
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Pharmacogenomics
Shortened title:Pharmacogenomics
Publisher:Future Medicine
ISSN:1744-8042
COBISS.SI-ID:521752601 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208-2022
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:I0-0022-2022
Name:Mreža raziskovalnih infrastrukturnih centrov Univerze v Ljubljani (MRIC UL)

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:I0-E011-2024
Name:Izvajanje mednarodnega infrastrukturnega projekta EATRIS

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:6-merkaptopurin, NUDT15, zmanjšanje odmerka, pogostnost manjšega alela, tiopurini


Back